retatrutide type 2 diabetes phase 2 results 2024 ada Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 🚨Breaking: Retatrutide's first Phase 3

A narrative synthesis approach was used to summarize findings across studies due to variability in study designs and outcome measures

Phase 3 TRIUMPH results are expected in 2026 and 2027, and Health Canada approval is likely in 2027 or 2028 if the late data holds up

The EMA performs a similar function for medicines approved across the European Union

If you reconstitute a 30 mg vial with sterile water and plan to draw doses over several weeks, you are creating a contamination risk that increases with every injection

What are some indicators that a patient with skin concerns after weight loss should be referred to a plastic surgeon

CrossRef Liver-specific inactivation of Cideb improves metabolic profiles and ameliorates steatohepatitis and fibrosis in animal models for MASH Jianhua Zhang, Xujie Liu, Xian Jin, Xudong Mao, Xueli Xu, Xing Zhang, Ke Shang, Yuan Xu, Yanhuan Zhang, Guofeng Meng, Ming Yue, Guoqing Cai, Song Yang, Jinyu Huang, Jianwu Fang, Ling Pan, Lei Jiang, Stella Shi, Jianyong Shou Pharmacological Research .2025